Plus   Neg

Teva To Discontinue Fremanezumab Development Program - Quick Facts

Teva Pharmaceutical Industries Ltd. (TEVA) said it is discontinuing the clinical development program for use of fremanezumab in cluster headaches as a pre-specified futility analysis of a Phase III study showed that the primary endpoint is unlikely to be met. Also, Teva is stopping the ENFORCE Phase III clinical trial program.

Teva said it continues to explore other uses for fremanezumab, including the treatment of post-traumatic headache.

Fremanezumab is an investigational compound in the treatment of cluster headache or post-traumatic headache.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the third quarter on Thursday, branded food company Hormel Foods Corp. (HRL) reaffirms its earnings guidance for the full-year 2019, while trimming annual net sales outlook as its navigates near-term uncertainty related to African swine fever. For fiscal 2019,... The U.S. Food and Drug Administration has issued a warning letter to Ningbo Huize Commodity Co., an over-the-counter drug manufacturer, for significant current good manufacturing practice violations, including data integrity issues. The warning letter issued to Ningbo Huize details a failure to have... Crate and Barrel have recalled 1,500 push walkers due to risk of choking and laceration. Crate and Barrel have recalled Activity Push Walkers as those walkers can be damaged over time exposing sharp points and small parts, posing choking and laceration hazards to small children. The wooden recalled...
Follow RTT